1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Metronidazole 500 mg IV Infusion

Trade Name: Flagyl
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as antiprotozoal agent

2. HAZARDS IDENTIFICATION

Appearance: Pale greenish/yellow sterile solution

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:
- **Short Term:** Ingestion of large amounts may cause central nervous system effects.
- **Long Term:** Animal studies have shown a potential to cause adverse effects on the fetus. Suspected of causing cancer.

Known Clinical Effects: Clinical use of this drug has caused peripheral neuropathy, associated with numbness and tingling of the extremities, pain, and motor weakness. Effects on blood and blood-forming organs have also occurred.

EU Indication of danger: Not classified

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous</th>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Metronidazole</td>
<td>443-48-1</td>
<td>207-136-1</td>
<td>Xn;R40-63</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td>Citric Acid</td>
<td>77-92-9</td>
<td>201-069-1</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

|           | Sodium Phosphate | 7632-05-5 | 231-558-5 | Not Listed | * |

METRONIDAZOLE 500 MG IV INFUSION
MATERIAL SAFETY DATA SHEET

Material Name: Metronidazole 500 mg IV Infusion
Revision date: 28-Aug-2009

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>Health Identification</th>
<th>Toxicological Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM CHLORIDE</td>
<td>7647-14-5</td>
<td>231-598-3</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Water for Injection</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
7. HANDLING AND STORAGE

**General Handling:**
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**Storage Conditions:**
Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

**Metronidazole**

<table>
<thead>
<tr>
<th>Country</th>
<th>OEL - TWA</th>
<th>Listed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Netherlands</td>
<td>Listed</td>
<td></td>
</tr>
</tbody>
</table>

**SODIUM CHLORIDE**

<table>
<thead>
<tr>
<th>Country</th>
<th>OEL - TWA</th>
<th>Listed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latvia</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Lithuania</td>
<td>Listed</td>
<td></td>
</tr>
</tbody>
</table>

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

**Pfizer Occupational Exposure Band (OEB):**

OEB2 (control exposure to the range of >100ug/m³ to < 1000ug/m³)

**Engineering Controls:**
Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Environmental Exposure Controls:**
Refer to specific Member State legislation for requirements under Community environmental legislation.

**Personal Protective Equipment:**
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

<table>
<thead>
<tr>
<th>Part</th>
<th>Protection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hands</td>
<td>Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.</td>
</tr>
<tr>
<td>Eyes</td>
<td>Wear safety glasses or goggles if eye contact is possible.</td>
</tr>
<tr>
<td>Skin</td>
<td>Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.</td>
</tr>
<tr>
<td>Respiratory protection</td>
<td>If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.</td>
</tr>
</tbody>
</table>

9. PHYSICAL AND CHEMICAL PROPERTIES

**Physical State:** Solution

**Molecular Formula:** Mixture

**Color:** Clear greenish/yellow

**Molecular Weight:** Mixture
10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Metronidazole
- Rat Oral LD50 3 g/kg
- Mouse Oral LD50 3800 mg/kg
- Mouse Intraperitoneal LD50 870 mg/kg

SODIUM CHLORIDE
- Rat Inhalation LC50/1hr > 42 g/m³
- Rat Oral LD50 3 g/kg
- Mouse Oral LD50 4 g/kg
- Rabbit Dermal LD50 > 10 g/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Metronidazole
- Eye Irritation Rabbit No effect

SODIUM CHLORIDE
- Skin Irritation Rabbit Mild
- Eye Irritation Rabbit Mild

Citric Acid
- Eye Irritation Rabbit Severe
- Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Metronidazole
- 2 Year(s) Mouse Oral 600 mg/kg LOAEL
- 80 Week(s) Rat Oral 30 mg/kg LOAEL
- 34 Day(s) Rat Oral = 34 g/kg LOAEL Kidney Ureter Bladder
- 4 Month(s) Dog Oral 75 mg/kg LOAEL
- 1 Year(s) Non-human Primate Oral 150 mg/kg LOAEL

Repeated Dose Toxicity Comments: Metronidazole produced tumors in mice and rats.

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Metronidazole
- Reproductive & Fertility Rat Oral 400 mg/kg LOAEL Fertility
11. TOXICOLOGICAL INFORMATION

Reproductive & Fertility
- Rabbit Oral 200 mg/kg NOAEL Fertility, Developmental toxicity, Fetotoxicity
- Embryo / Fetal Development Mouse Intraperitoneal 9 mg/kg LOAEL Fetotoxicity
- Embryo / Fetal Development Rat Oral 200 mg/kg NOEL Not Teratogenic
- Embryo / Fetal Development Mouse Intraperitoneal 40 mg/kg LOAEL Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Metronidazole
- In Vivo Bacterial Mutagenicity (Ames) Salmonella Positive
- In Vivo Sister Chromatid Exchange Hamster Negative
- In Vivo Unscheduled DNA Synthesis Rabbit Negative
- In Vivo Micronucleus Rat Negative
- In Vivo Chromosome Aberration Human Lymphocytes Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Metronidazole
- Not specified Rat Oral Tumors
- Not specified Mouse Oral Tumors

Carcinogen Status: See below

Metronidazole
- IARC: Group 2B
- NTP: Listed
- OSHA: Present

12. ECOLOGICAL INFORMATION

Environmental Overview:
Environmental properties of the formulation have not been thoroughly investigated.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Metronidazole
- Mysid Shrimp OECD LC-50 96 Hours >180 mg/L
- Sheepshead Minnow OECD LC-50 96 Hours >1060 mg/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures:
Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
14. TRANSPORT INFORMATION

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:
Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications
WHMIS hazard class:
Class D, Division 2, Subdivision A

Metronidazole
California Proposition 65: Listed; Cancer
Australia (AICS): Listed
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
EU EINECS/ELINCS List: 207-136-1

Sodium Phosphate
Inventory - United States TSCA - Sect. 8(b): Listed
Australia (AICS): Listed
EU EINECS/ELINCS List: 231-558-5

SODIUM CHLORIDE
Inventory - United States TSCA - Sect. 8(b): Listed
Australia (AICS): Listed
EU EINECS/ELINCS List: 231-598-3

Citric Acid
Inventory - United States TSCA - Sect. 8(b): Listed
Australia (AICS): Listed
EU EINECS/ELINCS List: 201-069-1

Water for Injection
Inventory - United States TSCA - Sect. 8(b): Listed
Australia (AICS): Listed
REACH - Annex IV - Exemptions from the obligations of Register: Present
EU EINECS/ELINCS List: 231-791-2
15. REGULATORY INFORMATION

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R40 - Limited evidence of a carcinogenic effect
R63 - Possible risk of harm to the unborn child.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision:
Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet